Impact of Bevacizumab on Liver Damage After Massive Hepatectomy in Rats.
Animals
Antineoplastic Agents, Immunological
/ adverse effects
Bevacizumab
/ adverse effects
Biomarkers
Chemical and Drug Induced Liver Injury
/ etiology
Cytokines
/ genetics
Gene Expression
Hepatectomy
Liver
/ drug effects
Liver Function Tests
Liver Regeneration
Male
Postoperative Period
Rats
Time Factors
Bevacizumab
endoplasmic reticulum stress
massive hepatectomy
preconditioning
unfolded protein response
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
10
06
2019
revised:
08
07
2019
accepted:
12
07
2019
entrez:
1
9
2019
pubmed:
1
9
2019
medline:
29
1
2020
Statut:
ppublish
Résumé
The aim of this study was to evaluate the impact of pretreatment with bevacizumab on liver damage in a rat model of massive hepatectomy (Hx) model, as a surrogate model of massive Hx for liver metastasis from colorectal cancer. Male Wister rats (n=24) were separated into the following two groups: 90% Hx and 90% Hx plus bevacizumab group. Bevacizumab (5 mg/kg) was injected intraperitoneally 7 days before Hx. Samples of blood and remnant liver tissue were obtained 24 hours after hepatectomy and the following parameters were evaluated: Biochemical analysis; liver regeneration rate; survival rate; and real-time polymerase chain reaction for interleukin-1 beta (Il1b), tumor necrosis factor alpha (Tnfa), matrix metalloproteinase (Mmp) 2 and Mmp9 mRNA. In addition, samples of whole liver tissue were obtained immediately before Hx and real-time polymerase chain reaction was performed for X-box binding protein 1 (Xbp1), activating transcription factor 6 (Atf6), C/EBP homologous protein (Chop), glucose-regulated protein 78 (Grp78) and heat-shock protein 70 (Hsp70), as markers of endoplasmic reticulum stress response. The levels of transaminases 24 hours after Hx were significantly reduced in the group pretreated with bevacizumab compared to that not pretreated (p<0.05). The liver regeneration rate at 24 hours after Hx was significantly increased in the group pretreated with bevacizumab compared with the group which underwent Hx alone (p<0.05). The survival rate for the group pretreated with bevacizumab tended to be higher than that of the Hx-only group, 72 hours after Hx (p=0.09). The expressions of Il1b, Mmp2 and Mmp9 mRNA 24 hours after Hx in the group pretreated with bevacizumab tended to be lower than that of rats which underwent Hx alone (p=0.11, 0.09 and 0.15, respectively). The expression of Xbp1, Chop, Grp78 and Hsp70 mRNA immediately before Hx in the group pretreated with bevacizumab were significantly higher than the 90% Hx group (p<0.05). Bevacizumab pretreatment had protective effects on liver injury after massive hepatectomy in rats, apparently via the induction of the endoplasmic reticulum stress response, i.e. the so-called unfolded protein response.
Sections du résumé
BACKGROUND
BACKGROUND
The aim of this study was to evaluate the impact of pretreatment with bevacizumab on liver damage in a rat model of massive hepatectomy (Hx) model, as a surrogate model of massive Hx for liver metastasis from colorectal cancer.
MATERIALS AND METHODS
METHODS
Male Wister rats (n=24) were separated into the following two groups: 90% Hx and 90% Hx plus bevacizumab group. Bevacizumab (5 mg/kg) was injected intraperitoneally 7 days before Hx. Samples of blood and remnant liver tissue were obtained 24 hours after hepatectomy and the following parameters were evaluated: Biochemical analysis; liver regeneration rate; survival rate; and real-time polymerase chain reaction for interleukin-1 beta (Il1b), tumor necrosis factor alpha (Tnfa), matrix metalloproteinase (Mmp) 2 and Mmp9 mRNA. In addition, samples of whole liver tissue were obtained immediately before Hx and real-time polymerase chain reaction was performed for X-box binding protein 1 (Xbp1), activating transcription factor 6 (Atf6), C/EBP homologous protein (Chop), glucose-regulated protein 78 (Grp78) and heat-shock protein 70 (Hsp70), as markers of endoplasmic reticulum stress response.
RESULTS
RESULTS
The levels of transaminases 24 hours after Hx were significantly reduced in the group pretreated with bevacizumab compared to that not pretreated (p<0.05). The liver regeneration rate at 24 hours after Hx was significantly increased in the group pretreated with bevacizumab compared with the group which underwent Hx alone (p<0.05). The survival rate for the group pretreated with bevacizumab tended to be higher than that of the Hx-only group, 72 hours after Hx (p=0.09). The expressions of Il1b, Mmp2 and Mmp9 mRNA 24 hours after Hx in the group pretreated with bevacizumab tended to be lower than that of rats which underwent Hx alone (p=0.11, 0.09 and 0.15, respectively). The expression of Xbp1, Chop, Grp78 and Hsp70 mRNA immediately before Hx in the group pretreated with bevacizumab were significantly higher than the 90% Hx group (p<0.05).
CONCLUSION
CONCLUSIONS
Bevacizumab pretreatment had protective effects on liver injury after massive hepatectomy in rats, apparently via the induction of the endoplasmic reticulum stress response, i.e. the so-called unfolded protein response.
Identifiants
pubmed: 31471394
pii: 33/5/1469
doi: 10.21873/invivo.11626
pmc: PMC6754989
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers
0
Cytokines
0
Bevacizumab
2S9ZZM9Q9V
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1469-1476Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
J Clin Exp Hepatol. 2014 Dec;4(4):332-46
pubmed: 25755580
FEBS J. 2019 Jan;286(2):241-278
pubmed: 30027602
Invest Ophthalmol Vis Sci. 2010 Dec;51(12):6524-32
pubmed: 20574016
Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):463-7
pubmed: 19735869
Nat Rev Mol Cell Biol. 2012 Jan 18;13(2):89-102
pubmed: 22251901
Trends Cell Biol. 2017 Oct;27(10):722-737
pubmed: 28647092
Clin Res Hepatol Gastroenterol. 2016 Sep;40(4):378-85
pubmed: 27038846
Cancer. 2007 Dec 15;110(12):2761-7
pubmed: 17960603
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S405-13
pubmed: 24570379
Annu Rev Genet. 2012;46:165-83
pubmed: 22934644
Life Sci. 2019 Jun 1;226:156-163
pubmed: 30978349
Int J Biochem Cell Biol. 2012 Aug;44(8):1295-8
pubmed: 22564438
Rev Invest Clin. 2018;70(6):279-284
pubmed: 30532115
In Vivo. 2018 Nov-Dec;32(6):1409-1417
pubmed: 30348695
Biotechnol Bioeng. 2011 Dec;108(12):2777-93
pubmed: 21809331
Cell Death Dis. 2012 Feb 16;3:e272
pubmed: 22337234
Gastroenterology. 2003 Sep;125(3):882-90
pubmed: 12949732
Cancer J. 2010 May-Jun;16(3):220-5
pubmed: 20526100
PLoS One. 2018 Jun 7;13(6):e0198099
pubmed: 29879147
J Cell Biol. 2010 May 31;189(5):783-94
pubmed: 20513765
Front Physiol. 2017 Feb 08;8:74
pubmed: 28228736
J Hepatobiliary Pancreat Sci. 2015 Aug;22(8):634-45
pubmed: 25926024
Clin Cancer Res. 2010 Aug 1;16(15):3887-900
pubmed: 20554752
BMC Cancer. 2016 Aug 24;16:677
pubmed: 27558497
Science. 2011 Nov 25;334(6059):1081-6
pubmed: 22116877
Mol Med Rep. 2017 May;15(5):3147-3152
pubmed: 28358421
Invest Ophthalmol Vis Sci. 2010 Sep;51(9):4585-8
pubmed: 20357189
Ann Oncol. 2015 Apr;26(4):702-8
pubmed: 25538173
BMC Cancer. 2012 Mar 13;12:89
pubmed: 22414244
Am J Surg. 2010 Aug;200(2):270-5
pubmed: 20227057
J Surg Res. 2017 Aug;216:191-200
pubmed: 28807207
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
J Biol Chem. 2019 Feb 8;294(6):2098-2108
pubmed: 30563838
Ann Oncol. 2010 Jun;21(6):1152-62
pubmed: 19942597
Anticancer Res. 2014 Apr;34(4):1953-8
pubmed: 24692731